SCHEMBL25514004

SCHEMBL25514004

Cc1cc2c(n1Cc1ccc(C(C)C)cc1)CCCC2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
PABPC1 P11940 1/20 0.45
TSHR P16473 1/20 0.45
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
HPGD P15428 2/20 0.39
MAPT P10636 2/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HRH3 Q9Y5N1 1/20 0.38
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25514178 0.87 BRD4 (0.54) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL22916953 0.85 BRD4 (0.73) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL25514185 0.84 BRD4 (0.54) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL22917040 0.81 BRD4 (0.46) BRD4SMN1; SMN2KMT2ATSHRHPGD
SCHEMBL25514182 0.81 BRD4 (0.51) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL25514199 0.81 BRD4 (0.51) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL25514196 0.81 BRD4 (0.54) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL25514686 0.78 BRD4 (0.43) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL22917189 0.76 BRD4 (0.42) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL25514682 0.76 BRD4 (0.41) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 BRD4 2025/4885SMN1; SMN2 376/4885ALDH1A1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.